Nierenzelltumore

A randomized, controlled Phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma

Study Code IMA901-301

EudraCT-Nr.: 2010-022459-45

Sponsor: Immatics biotechnolgies GmbH/Tübingen

LKP: Prof. Dr. A. Stenzl/Tübingen

Hauptprüfer in Ulm: Prof. Dr. Jochen Greiner

Prüfärzte: Dr. Anna Babiak, Dr. Marie-Luise Hütter, Dr. Miriam Kull, Dr. Regine Mayer-Steinacker, Prof. Dr. Richard Schlenk, Dr. Dirk Winkler 

Dokumentation und Studienassistenz: Katrin Mann, Ursula Volk

Prospective randomized phase-II trial with Temsirolimus versus Sunitinib in previously untreated patients with advanced or metastatic non-clear cell renal carcinoma

CESAR C-II-006

EudraCT-Nr.: 2009-010143-13

Sponsor: CESAR Central European Society for Anticancer Drug Research-EWIV

LKP: Prof. Dr. Lothar Bergmann

Hauptprüfer in Ulm: Prof. Dr. Jochen Greiner

Prüfärzte: Dr. Marie-Luise Hütter, Dr. Miriam Kull, Dr. Regine Mayer-Steinacker, Prof. Dr. Richard Schlenk, Dr. Manuela Wölfle-Guter, Prof. Dr. Lars Bullinger

Dokumentation und Studienassistenz: Katrin Mann, Ursula Volk

Rekrutierungsphase abgeschlossen 05.01.2012

A phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by sunitinib versus sunitinib followed by sorafenib in the treatment of first-line advanced / metastatic renal cell carcinoma.

RCC Sequential Study (SWITCH)

EudraCT-Nr.: 2008-005011-18

Sponsor: Deutsche Krebsgesellschaft Sponsor GmbH, Berlin

LKP: Prof. Dr. Maurice-Stephan Michel, Mannheim

Hauptprüfer in Ulm: Prof. Dr. Jochen Greiner

Prüfärzte: PD Dr. Martin Bommer, Dr. Beate Grüner, Dr. Marie-Luise Hütter, Dr. Miriam Kull, Dr. Regine Mayer-Steinacker, Prof. Dr. Richard Schlenk, Prof. Dr. Lars Bullinger

Dokumentation und Studienassistenz: Ursula Volk, Katrin Mann

Rekrutierungsphase abgeschlossen am 23.3.2011

A randomized trial of Temsirolimus and Sorafenib as second-line Therapy in patients with advanced renal cell carcinoma who have failed first line Sunitinib therapy.

CCI 404

Sponsor: Wyeth Pharma,  Münster

Hauptprüfer in Ulm: Prof. Dr. Jochen Greiner

Prüfärzte: Dr. Beate Grüner, Dr. Regine Mayer-Steinacker, PD Dr. Martin Bommer, Prof. Dr. Donald Bunjes, Prof. Dr. Konstanze Döhner, Prof. Dr. Richard Schlenk, Prof. Dr. Stephan Stilgenbauer, PD Dr. Andreas Viardot

Dokumentation und Studienassistenz:  Katrin Mann, Ursula Volk